9939
vs
H
Hang Seng (Hong Kong)
9939
Over the past 12 months, Kintor Pharmaceutical Ltd has significantly outperformed Hang Seng (Hong Kong), delivering a return of +148% compared to the Hang Seng (Hong Kong)'s +13% growth.
Stocks Performance
9939 vs Hang Seng (Hong Kong)
Performance Gap
9939 vs Hang Seng (Hong Kong)
Performance By Year
9939 vs Hang Seng (Hong Kong)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Kintor Pharmaceutical Ltd
Glance View
Kintor Pharmaceutical Ltd. is a clinical-stage novel drug developer in China, which focuses on the proprietary research and development of innovative medicine products for cancers and other Androgen receptor-related diseases. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-05-22. The firm is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The firm are also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib and an inhibitor of the hedgehog signal translation pathway GT1708F.
